2025-11-12T17:59:04-06:00 2024-12-31 420714325 RSM US LLP 919 EAST MAIN STREET SUITE 1800 RICHMOND VA 23219 990 2024-01-01 921555633 BLACKBIRD LABORATORIES INC BLAC 2029425355 101 WEST DICKMAN ST 100 BALTIMORE MD 21230 MATT TREMBLAY CEO 2029425355 2025-11-06 1 1 MEREDITH BELL P01696827 8042822121 2025-11-06 2024 2025-03-06 01:10:19Z MATT TREMBLAY 101 WEST DICKMAN ST 100 BALTIMORE MD 21230 4297621 0 X WWW.BLACKBIRDLAB.ORG X 2023 DE BLACKBIRD LABORATORIES IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION BASED IN BALTIMORE THAT IS FOCUSED ON CONDUCTING MEDICAL AND SCIENTIFIC RESEARCH IN CONJUNCTION WITH NONPROFIT HOSPITALS AND ACADEMIC INSTITUTIONS, SPECIFICALLY TO HELP MARYLAND'S UNIVERSITIES AND INVESTIGATORS AMPLIFY THE IMPACT OF THEIR ACADEMIC RESEARCH, BUILD INNOVATIVE COMPANIES, BRING TRANSFORMATIVE TECHNOLOGIES TO LIFE, AND CREATE A THRIVING ENTREPRENEURIAL ECOSYSTEM IN MARYLAND. 3 2 15 2 0 0 88178653 4203859 0 22571 0 71191 800 0 88179453 4297621 0 0 0 0 2305663 3578205 0 0 0 2968971 4671431 5274634 8249636 82904819 -3952015 83366299 85463986 461480 6511182 82904819 78952804 X BLACKBIRD LABORATORIES IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION BASED IN BALTIMORE THAT IS FOCUSED ON CONDUCTING MEDICAL AND SCIENTIFIC RESEARCH IN CONJUNCTION WITH NONPROFIT HOSPITALS AND ACADEMIC INSTITUTIONS, SPECIFICALLY TO HELP MARYLAND'S UNIVERSITIES AND INVESTIGATORS AMPLIFY THE IMPACT OF THEIR ACADEMIC RESEARCH, BUILD INNOVATIVE COMPANIES, BRING TRANSFORMATIVE TECHNOLOGIES TO LIFE, AND CREATE A THRIVING ENTREPRENEURIAL ECOSYSTEM IN MARYLAND. 0 0 7199305 22571 BLACKBIRD LABORATORIES IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION BASED IN BALTIMORE, MARYLAND, WHICH CONDUCTS LIFE SCIENCES RESEARCH IN THE PURSUIT OF NEW TREATMENTS FOR DISEASES IN COLLABORATION WITH NONPROFIT HOSPITALS, ACADEMIC INSTITUTIONS, AND OTHER MEDICAL RESEARCH ORGANIZATIONS. SPECIFICALLY, WE AIM TO HELP MARYLAND'S UNIVERSITIES AND INVESTIGATORS AMPLIFY THE IMPACT OF THEIR ACADEMIC RESEARCH BY BRINGING TRANSFORMATIVE TECHNOLOGIES TO LIFE AND SUPPORTING START-UP FORMATION AND DEVELOPMENT. OUR GOAL IS TO BRIDGE THE GAP BETWEEN PIONEERING SCIENTIFIC RESEARCH AND INDUSTRY BY PROVIDING PROGRAM MANAGEMENT, STRATEGIC SCIENTIFIC AND BUSINESS COLLABORATION, AND FINANCIAL SUPPORT. OUR TEAM OF LIFE SCIENCES PROFESSIONALS FACILITATES THE DEVELOPMENT OF INNOVATIVE BIOTECHNOLOGY COMPANIES BY ADVANCING PROMISING TRANSLATIONAL TECHNOLOGY INTO NEW MEDICINES AND MEDICAL TREATMENTS FOR PATIENTS, ATTRACTING INVESTMENT, AND NURTURING BALTIMORE'S POTENTIAL TO BE A LIFE SCIENCES LEADER ON THE NATIONAL STAGE.IN FISCAL YEAR 2024, THE BLACKBIRD LABORATORIES TEAM EVALUATED OVER 200 POTENTIAL PROJECTS AND ESTABLISHED 4 NEW RESEARCH PROGRAMS FOR A TOTAL OF 9 COLLABORATIVE PROJECTS WITH NONPROFIT HOSPITAL AND ACADEMIC INSTITUTIONS (JOHNS HOPKINS UNIVERSITY AND THE UNIVERSITY OF MARYLAND) AND OTHER MEDICAL RESEARCH ORGANIZATIONS (THE LIEBER INSTITUTE FOR BRAIN DEVELOPMENT). THE ULTIMATE GOAL OF THESE COLLABORATIONS IS TO DEVELOP PIONEERING THERAPEUTICS RESEARCH INTO SUCCESSFUL SPINOUT COMPANIES WORKING TO ADDRESS GAPS IN AVAILABLE TREATMENT OPTIONS FOR PATIENTS. MANY BREAKTHROUGH MEDICINES AND TECHNOLOGIES THAT SERVE THE PUBLIC INTEREST FAIL TO PROGRESS TO MARKET BECAUSE OF A LACK OF FUNDING OR A LACK OF TECHNICAL EXPERTISE TO MANAGE THE STARTUPS LAUNCHED TO SHEPHERD THESE PRODUCTS TO MARKET. TO OVERCOME THESE BARRIERS, BLACKBIRD LABORATORIES ADVISES THESE STARTUP COMPANIES AND CONNECTS THEM WITH VENTURE CAPITAL FIRMS, ULTIMATELY ENSURING THAT MEDICAL INNOVATIONS REACH PATIENTS AS QUICKLY AND EFFECTIVELY AS POSSIBLE. ANOTHER KEY TENET OF BLACKBIRD LABORATORIES' MISSION TO CATALYZE AND MAINTAIN A THRIVING ENTREPRENEURIAL ECOSYSTEM IN BALTIMORE IS THE RETENTION AND ADVANCEMENT OF LOCAL LIFE SCIENCES TALENT. TWO FIFTH-YEAR PHD STUDENTS AND ONE RECENT PHD GRADUATE COMPRISED BLACKBIRD LABORATORIES SECOND VENTURE FELLOWS CLASS - A PAID FELLOWSHIP PROGRAM LAUNCHED IN 2023 TO ENABLE DIRECT EXPOSURE TO ENTREPRENEURSHIP IN THE LIFE SCIENCES INDUSTRY. FURTHER, BLACKBIRD LABORATORIES CONTINUES FOSTERING MENTORSHIP AND TRAINING OPPORTUNITIES BY ORGANIZING AND HOSTING VARIOUS SCIENTIFIC TALKS, PRESENTATIONS, AND OTHER PROGRAMS THAT ARE OPEN TO LOCAL SCIENTISTS AND STUDENTS, AS WELL AS AMPLIFYING THE ECOSYSTEM DEVELOPMENT WORK ALREADY BEING CONDUCTED LOCALLY THROUGH SPONSORSHIP AND COLLABORATION.IN ADDITION TO NURTURING LOCAL TALENT, BLACKBIRD LABORATORIES IS CURRENTLY ESTABLISHING 42,000 SQ FT OF ADDITIONAL WET LAB CAPACITY (BLACKBIRD BIOHUB) WITHIN BALTIMORE CITY. BLACKBIRD BIOHUB WILL NOT ONLY SUPPORT BLACKBIRD LABORATORIES' OWN MEDICAL AND SCIENTIFIC RESEARCH BUT ALSO FOSTER THE SUCCESS OF FLEDGLING BIOTECHNOLOGY COMPANIES BY FACILITATING THEIR RETENTION, IN TURN HELPING TO CREATE A THRIVING ENTREPRENEURIAL ECOSYSTEM FOR LIFE SCIENCES COMPANIES IN BALTIMORE. 7199305 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 37 0 1 15 1 0 0 0 0 0 0 0 0 0 0 0 0 X 3 2 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 1 1 0 MD X EMILY WILKINSON 2029425355 101 WEST DICKMAN ST 100 BALTIMORE MD 21230 MATT TREMBLAY CEO & BOARD MEMBER, TREASURER 32.00 X X 656996 0 50884 RYLAND SUMNER BOARD CHAIR 1.00 X 0 0 0 MARK EDWARDS BOARD MEMBER 1.00 X 0 0 0 EMILY WILKINSON DIR, FIN & OPS, CORP SEC/TREAS 40.00 X 165810 0 31314 ALEKSANDRA BARANCZAK CHIEF PROGRAM OFFICER 38.00 X 422666 0 25489 EDWARD CHEROK CHIEF BUSINESS OFFICER 36.00 X 411267 0 17443 ANTHONY ACCORSI VENTURE PARTNER 40.00 X 467278 0 23284 MATTHEW LAWLER ENTREPRENEUR-IN-RESIDENCE 40.00 X 230152 0 11575 YIXUAN QIU ASSOCIATE DIRECTOR, RESEARCH PROGRAMS 40.00 X 153932 0 15303 VIRGINA BURGER ENTREPRENEUR-IN-RESIDENCE 40.00 X 235649 0 11827 2743750 0 187119 8 0 1 0 EUROFINS BEACON DISCOVERY INC 6118 NANCY RIDGE DR SAN DIEGO CA 92121 CONTRACT RESEARCH 140844 1 4203859 4203859 SERVICE REVENUE 900099 22571 22571 22571 63391 63391 7800 0 7800 7800 7800 4297621 22571 0 71191 1781869 1512849 269020 1535021 1313611 221410 56289 46588 9701 46238 32223 14015 158788 132435 26353 46130 46130 85529 85529 69813 69813 30342 27944 2398 95844 77239 18605 137794 88364 49430 204315 204315 141057 133159 7898 14505 14505 12960 12960 12754 12754 SCIENTIFIC PROGRAM 3820388 3820388 8249636 7199305 1050331 0 2421150 3096259 0 164675 80094653 75915512 500000 630500 60357 31064 137891 13490 69380 124401 220759 5501575 83366299 85463986 233931 968639 227549 5542543 461480 6511182 X 2810166 3037292 80094653 75915512 82904819 78952804 83366299 85463986 -3952015 0 X 0 1 X 1 0 X 88178653 4203859 92382512 88178653 4203859 92382512 90533578 1848934 63391 63391 800 800 92446703 22571 X PART II, SHORT YEAR EXPLANATION: THE ORGANIZATION BEGAN OPERATIONS ON JANUARY 3, 2023. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 62956 13490 49466 74935 74935 124401 DEPOSITS 62478 RIGHT-OF-USE ASSETS 5439097 5501575 LEASE LIABILITIES 5542543 5542543 X 4297621 0 4297621 0 4297621 8249636 0 8249636 0 8249636 PART X, LINE 2: THE ORGANIZATION ADOPTED THE ACCOUNTING STANDARD ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH ADDRESSES THE DETERMINATION OF WHETHER TAX BENEFITS CLAIMED OR EXPECTED TO BE CLAIMED ON A TAX RETURN SHOULD BE RECORDED IN THE FINANCIAL STATEMENTS. UNDER THIS POLICY, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WOULD BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. MANAGEMENT HAS EVALUATED THE ORGANIZATIONS TAX POSITIONS, AND HAS CONCLUDED THAT THE ORGANIZATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS GUIDANCE. X X X 0 0 0 0 0 0 0 1 0 MATT TREMBLAY CEO & BOARD MEMBER, TREASURER 656996 0 0 0 0 0 17250 0 33634 0 707880 0 0 0 ANTHONY ACCORSI VENTURE PARTNER 288134 0 157201 0 21943 0 9618 0 13666 0 490562 0 0 0 ALEKSANDRA BARANCZAK CHIEF PROGRAM OFFICER 325994 0 96672 0 0 0 17250 0 8239 0 448155 0 0 0 EDWARD CHEROK CHIEF BUSINESS OFFICER 318386 0 92881 0 0 0 16966 0 477 0 428710 0 0 0 VIRGINA BURGER ENTREPRENEUR-IN-RESIDENCE 189449 0 46200 0 0 0 11782 0 45 0 247476 0 0 0 MATTHEW LAWLER ENTREPRENEUR-IN-RESIDENCE 191804 0 38348 0 0 0 11508 0 67 0 241727 0 0 0 EMILY WILKINSON DIR, FIN & OPS, CORP SEC/TREAS 149892 0 15918 0 0 0 8757 0 22557 0 197124 0 0 0 YIXUAN QIU ASSOCIATE DIRECTOR, RESEARCH PROGRAM 123640 0 24720 0 5572 0 7697 0 7606 0 169235 0 0 0 PART I, LINE 7 DISCRETIONARY BONUSES WERE PAID IN 2024. ANTHONY ACCORSI VENTURE PARTNER, HIGHLY COMPENSATED EMPLOYEE PURCHASE OF A PRINCIPAL RESIDENCE TO RELOCATE TO MARYLAND X 130500 130500 0 1 1 MATT TREMBLAY CEO AND BOARD MEMBER PURCHASE OF A PRINCIPAL RESIDENCE TO RELOCATE TO MARYLAND X 500000 500000 0 1 1 630500 FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT COPY OF THE 990 WILL BE PROVIDED TO BLACKBIRD LEADERSHIP AS WELL AS THE BOARD OF DIRECTORS FOR COMMENT AND REVIEW PRIOR TO FILING. BLACKBIRD LEADERSHIP IS AN INTEGRAL PART OF PREPARING THE 990 FORM ALONGSIDE THE 990 PREPARERS. FORM 990, PART VI, SECTION B, LINE 12C THE INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES DIRECTORS, OFFICERS, KEY EMPLOYEES AND OTHER DESIGNATED INDIVIDUALS TO DISCLOSE IF THEY HAVE A PERSONAL INTEREST OR RELATIONSHIP IN A TRANSACTION INVOLVING THE INSTITUTE, WHETHER DIRECTLY OR INDIRECTLY THROUGH A FAMILY MEMBER, CONTROLLED ENTITY OR BUSINESS OR INVESTMENT RELATIONSHIP. ANY INDIVIDUAL WITH A PERSONAL INTEREST OR RELATIONSHIP IN A TRANSACTION INVOLVING THE INSTITUTE MUST BE RECUSED FROM THE DISCUSSIONS AND APPROVAL FOR THAT TRANSACTION. THE TRANSACTION MUST BE REVIEWED BY DISINTERESTED PERSONS WHO DO NOT HAVE A PERSONAL INTEREST IN THE TRANSACTION UNDER REVIEW, AND SUCH DISINTERESTED PERSONS MAY APPROVE THE TRANSACTION AFTER DETERMINING THAT THE TERMS ARE FAIR AND REASONABLE TO THE INSTITUTE. THE INSTITUTE MAY ALSO CONSIDER WHETHER THERE ARE ALTERNATIVE TRANSACTIONS OR ARRANGEMENTS THAT ARE REASONABLY AVAILABLE UNDER THE CIRCUMSTANCES THAT DO NOT PRESENT A POTENTIAL CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 INDUSTRY DATA WAS UTILIZED TO DETERMINE COMPENSATION BENCHMARKS FOR THE CEO AND OTHER KEY EMPLOYEES. EXTERNAL CONSULTANTS, SUCH AS A FRACTIONAL CFO AND HUMAN RESOURCES PROFESSIONALS, WERE INCLUDED IN THE PROCESS TO DETERMINE APPROPRIATE AND REASONABLE COMPENSATION PACKAGES AND PRACTICES. THE CEO'S COMPENSATION WAS REVIEWED AND APPROVED BY THE BOARD. THIS PROCESS WAS INITIALLY COMPLETED DURING THE ONBOARDING OF THE CEO AND OTHER KEY PERSONNEL. SINCE THEN, EACH OF THESE INDIVIDUALS HAS RECEIVED ONLY MODEST ANNUAL COST-OF-LIVING ADJUSTMENTS, AND AS A RESULT, THE REVIEW PROCESS HAS NOT BEEN REVISITED. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D).